In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments

• Main Authors: Nardos G. Tassew, Philippe P. Monnier, Robin J. Vigouroux
• Format: Article
• Language: English
• Published: MDPI AG 2013-04-01
• Series: Antibodies
• Subjects: scFv; recombinant antibodies; in vivo expression; adeno-associated virus (AAV); immunotherapy
• Online Access: http://www.mdpi.com/2073-4468/2/2/193

Single chain variable domain (Fv) fragments (scFv) are powerful tools in research and clinical settings, owing to better pharmacokinetic properties compared to the parent monoclonal antibodies and the relative ease of producing them in large quantities, at low cost. Though they offer several advantages, they suffer from lower binding affinity and rapid clearance from circulation, which limits their therapeutic potential. However, these fragments can be genetically modified to enhance desirable properties, such as multivalency, high target retention and slower blood clearance, and as such, a variety of scFv formats have been generated. ScFvs can be administered by systemic injection for diagnostic and therapeutic purposes. They can be expressed in vivo through viral vectors in instances where large infection rates and sustenance of high levels of the antibody is required. ScFvs have found applications as tools for in vivo loss-of-function studies and inactivation of specific protein domains, diagnostic imaging, tumor therapy and treatment for neurodegenerative and infectious diseases. This review will focus on their in vivo applications.